ClinicalTrials.Veeva

Menu

METABolic Deterioration in HTX Determines Outcomes (METAB-HTX)

H

Heinrich-Heine University, Duesseldorf

Status

Enrolling

Conditions

Heart Transplantation

Study type

Observational

Funder types

Other

Identifiers

NCT07372820
METAB-HTX

Details and patient eligibility

About

METAB-HTX is a prospective, longitudinal cohort study evaluating cardiac and systemic metabolism in heart transplant recipients.

Full description

Bankground:

Heart Transplantation (HTS) is the treatment of choice for advanced heart failure, yet long-time survival rates require further improvement. Recent studies highlight obesity, type 2 diabetes, renal dysfunction, and hepatic impairment as key contributors to post-transplant mortality. Furthermore, critical questions persist in understanding the optimal metabolic surveillance post-HTX, the direct association between metabolic dysregulation and cardiac dysfunction, inter-organ interactions linking metabolic decline to hepatic/renal impairment and the timing of therapeutic strategies.

Therefore: METAB-HTX study aims to address these open questions, hypothesizing that metabolic deterioration post-HTX is associated with impaired cardiac function and survival.

Study Design:

The study employs advanced multi-modal phenotyping to investigate interactions between cardiac function, metabolic dysregulation, and systemic organ dysfunction.

Cardiac Phenotyping:

  • Imaging: Serial echocardiography, cardiac MRI (cMRI), and magnetic resonance spectroscopy (MRS) for myocardial structure, perfusion, and metabolic profiling.
  • Vascular Evaluation: Coronary angiography to detect macro- and microvascular coronary allograft vasculopathy (CAV).
  • Rejection Monitoring: Protocol-driven endomyocardial biopsies for histopathological grading.

Metabolic phenotyping:

  • Serial oral glucose tolerance tests, homeostasis model assessment, type 2 diabetes endotyping and muscle biopsies.
  • Advanced lipid panels, HDL functional assays and plasma membrane lipid fluidity analyses.
  • MRI/MRS-based quantification of adipose tissue distribution and ectopic fat deposition.

Systemic Organ Evaluation:

  • renal and liver function.

Molecular and Multi-Omics Integration:

  • Myocardial Energy Metabolism, Genomic/Transcriptomic Profiling, Thromoboinflammation and Neoplasia Risk.

This innovative study aims to bridge critical gaps in understanding post-transplant metabolic pathophysiology, potentially refining surveillance protocols and guiding targeted therapies to improve long-term survival through precision medicine strategies

Enrollment

270 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: ≥ 18 years
  • Planned or already conducted heart transplantation
  • Informed consent

Exclusion criteria

  • Absence of informed consent

Trial design

270 participants in 1 patient group

Adult advanced heart failure patients listed for HTx
Description:
Patients with advanced heat failure (AHF) and listed for heart transplantation (HTx)

Trial contacts and locations

1

Loading...

Central trial contact

Fabian Voß, Dr. med.; Amin Polzin, Prof.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems